Compare · ASLE vs EW
ASLE vs EW
Side-by-side comparison of AerSale Corporation (ASLE) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- ASLE operates in Consumer Discretionary, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $49.36B, about 172.7x ASLE ($285.9M).
- Over the past year, ASLE is up 4.6% and EW is up 11.9% - EW leads by 7.3 points.
- EW has been more active in the news (6 items in the past 4 weeks vs 2 for ASLE).
- EW has more recent analyst coverage (25 ratings vs 6 for ASLE).
- Company
- AerSale Corporation
- Edwards Lifesciences Corporation
- Price
- $6.04+0.17%
- $85.70-2.46%
- Market cap
- $285.9M
- $49.36B
- 1M return
- -3.75%
- -3.25%
- 1Y return
- +4.59%
- +11.92%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 2
- 6
- Recent ratings
- 6
- 25
AerSale Corporation
AerSale Corporation provides aftermarket commercial aircraft, engines, and its parts to passenger and cargo airlines, leasing companies, original equipment manufacturers, and government and defense contractors, as well as maintenance, repair, and overhaul (MRO) service providers worldwide. It operates in two segments, Asset Management Solutions and Technical Operations (TechOps). The Asset Management Solutions segment engages in the sale and lease of aircraft, engines, and airframes, as well as disassembly of these assets for component parts. The TechOps segment provides internal and third-party aviation services, including internally developed engineered solutions, heavy aircraft maintenance and modification, and component MRO, as well as storage and disassembly services. This segment also provides aircraft modifications, cargo/tanker conversions of aircraft, and aircraft storage; and MRO services for landing gear, thrust reversers, hydraulic systems, and other aircraft components. The company was founded in 2008 and is headquartered in Coral Gables, Florida.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest ASLE
- Officer Tschirhart Benjamin Thomas sold $505 worth of shares (77 units at $6.56) as part of a pre-agreed trading plan, decreasing direct ownership by 0.24% to 32,487 units (SEC Form 4) (withholding tax)
- B. Riley Securities initiated coverage on AerSale with a new price target
- AerSale Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Officer Pizzi Enrique sold $19,794 worth of shares (3,122 units at $6.34) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 81,224 units (SEC Form 4) (tax withholding)
- Officer Tschirhart Benjamin Thomas sold $11,958 worth of shares (1,886 units at $6.34) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 32,564 units (SEC Form 4) to satisfy withholding obligation
- Officer Jones Gary Edmund sold $47,495 worth of shares (7,491 units at $6.34) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 162,405 units (SEC Form 4) to satisfy withholding tax
- Officer Garmendia Martin sold $38,638 worth of shares (6,094 units at $6.34) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 183,377 units (SEC Form 4) (tax withholding)
- Officer Hechenberger Paul Andrew sold $10,056 worth of shares (1,586 units at $6.34) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,581 units (SEC Form 4) to cover withholding tax
- Officer Wright Frederick Craig sold $26,515 worth of shares (4,182 units at $6.34) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 213,531 units (SEC Form 4) (withholding tax)
- Director Nichols Robert B. was granted 19,623 shares (SEC Form 4)
Latest EW
- Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
- CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.53% to 20,628 units (SEC Form 4) (for withholding tax)
- CVP, Chief Financial Officer Mistras Theodora was granted 99,920 shares (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,762 worth of shares (619 units at $91.70) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TAVR Lippis Daniel J. covered exercise/tax liability with 377 shares, decreasing direct ownership by 0.93% to 40,034 units (SEC Form 4) to cover taxes
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,577 worth of shares (619 units at $91.40) as part of a pre-agreed trading plan (SEC Form 4)
- Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
- CEO Zovighian Bernard J sold $45,982 worth of shares (523 units at $87.92) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 11-K filed by Edwards Lifesciences Corporation